Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer

International Journal of Gynecological Cancer

Volumn 20, Issue 1, 2010, Pages 164-172

  Pérez Regadera, José ^a   Sánchez Muñoz, Alfonso ^a   De La Cruz, Javier ^a   Ballestín, Claudio ^a   Lora, David ^a   García Martín, Rosa ^a   Alonso Carrión, Lorenzo ^b   Mendiola, Cesar ^c   Lanzós, Eduardo ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Department of Medical Oncology   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Advanced cervical cancer; C erb B2 status; Chemoradiotherapy; Disease free survival; Local relapse rate

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TEGAFUR;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; ALLERGY; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; UTERINE CERVIX CANCER;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; TEGAFUR; TREATMENT OUTCOME; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 74249102156     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181ad3e11     Document Type: Article

References (42)

1. Pisan P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18-29.
2. Waggoner SE. Cervical cancer. Lancet. 2003;361:2217-2225.
3. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22:872-880. (Pubitemid 41103599)
4. Rose P, Bundy BN, Watkins EB, et al. Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;349:1144-1151.
5. Whitney CW, Sause D, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxiurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol. 1999;17:1339-1348.
6. Keys HM, Bundy BN, Stheman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant histerectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-1160.
7. Peters WA III, Liu PY, Barret RJ II, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high risk early stage carcinoma of the cervix. J Clin Oncol. 2000;18:1606-1613.
8. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing concurrent radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966-972.
9. ThomasGM. Improved treatment for cervical cancerVconcurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340: 1198-1199.
10. Benda JA. Histopathologic prognostic factors in early stage cervical carcinoma. J Natl Cancer Inst Monogr 1996;21:27-34.
11. Tanaka Y, Sawada S, Murata T, et al. Relationship between lymph node metastases and prognosis in patients irradiated postoperatively for carcinoma of the uterine cervix. Acta Radiol. 1984;23:455-459.
12. Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990; 38:352-357.
13. Akiyama T, Sudo C, Ogawara H, et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232:1644-1646. (Pubitemid 16095607)
14. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cell transfected with HER2/neu. Breast Cancer Res Treat. 1992;24:85-95.
15. Chazin VR, Kaleko M, Miller AD, et al. Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor. Oncogene. 1992;7:1859-1866.
16. Hudziak RM, Schlessinger J, Ullrich A. Increase expression of the putative growth factor receptor p185 causes transformation and tumorigenesis of HIH 3T3 cells. Proc Natl Acad Sci U S A. 1987;84:7159-7163.
17. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overespresses HER2. N Engl J Med. 2001;344:783-792.
18. Kristensen GB, Holm R, Abeler VM, et al. Evaluation of the prognosis significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. Cancer. 1996;78:433-440.
19. Oka K, Nakano T, Arai T. c-erB-2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer. 1994;664-671.
20. Kihana T, Tsuda H, Teshima S, et al. Prognostic significance of the overexpression of c-erbB2 protein in adenocarcinoma of the uterine cervix. Cancer. 1994;73:148-153.
21. Niibe Y, Nakano T, Ohno T, et al. Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. Int J Gynecol Cancer. 2003;13:849-855.
22. Lee JS, Kim HS, Jung JJ, et al. Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erB-2 protein expression. Gynecol Oncol. 2002;85:469-475.
23. Leung TW, Cheung AN, Cheng DK, et al. Expressions of c-erB-2, epidermal growth factor receptor and pan-ras proto-oncogenes in adenocarcinoma of the cervix: correlation with clinical prognosis. Oncol Rep. 2001;8:1159-1164.
24. Hove MG, Dinh TV, Hannigan EV, et al. Oncogene expression and microvessel count in recurrent and nonrecurrent stage Ib squamous cell carcinoma of the cervix. J Reprod Med. 1999;44: 493-496.
25. Hale RJ, Buckley CH, Fox H, et al. Prognostic value of c-erbB2 expression in uterine cervical carcinoma. J Clin Pathol. 1992; 45:594-596.
26. Kuniyuki O, Nakano T, Arai T. c-erbB-2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer. 1994;73:668-671.
27. Costa M, Walls J, Trelford JD. c-erbB-2 oncoprotein overexpression in uterine cervix cancer carcinoma with glandular differentiation. Am J Clin Pathol. 1995;104:634-643.
28. Wong YF, Chung TKH, Cheung TH, et al. Her-2/neu gene amplification in cervical cancer in Chinese women of Hong Kong and China. J Obstet Gynaecol Res. 1996;22:171-175.
29. Nakano T, Oka K, Ishikawa A, et al. Correlation of cervical carcinoma cerbB-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer. 1997;79:513-520.
30. Nevin J, Laing D, Kaye P, et al. The significance of c-erbB-2 immunostaining in cervical cancer. Gynecol Oncol. 1999;73: 354-358.
31. Mandain M, Konishi I, Koshiyama M, et al. Altered expression of nm23-H1 and cerbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer. 1994;75:2523-2529.
32. Ndubisi B, Sanz S, Lu L, et al. The prognostic value of Her-2/neu oncogene in cervical cancer. Ann Clin Lab Sci. 1997;27:396-401.
33. National Cancer Institute: NCI Clinical Announcement. Bethesda, MD: United States Department of Health and Human Services. Public Health Service, National Institute of Health, February 1999.
34. Hsu SM, Raine L, Fouger HA. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981;75: 734-738.
35. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
36. ICRU. Dose and volume specification for reporting intracavitary therapy in gynaecology, ICRU report 38. Bethesda, MD: International Commission on Radiation Units and Measurements; 1985.
37. Nishioka T, West CM, Gupta N, et al. Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy. J Cancer Res Clin Oncol. 1999;125:96-100.
38. Lanciano R, Calkins A, Bundy BN, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol. 2005;23:8289-8295.
39. Nag S, Chao C, Erickson B, et al; American Brachytherapy Society. The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2002;52:33-48. (Pubitemid 34041564)
40. Gerbaulet A, Pöter R, Haie-Meder C. Cervix Cancer. In: Gerbaulet A, Pöter R, Mazeron JJ, Meertens H, Van Limbergen E. Eds. The GEC ESTRO Handbook of Brachytherapy. Brussels: European Society of Therapeutic Radiology and Oncology; 2002 p:300-363.
41. Grigsby PW, Williamson JF, Clifford Chao KS, et al. Cervical tumor control evaluated with ICRU 38 reference volumes and integrated reference air kerma. Radiother Oncol. 2001;58: 19-23.
42. Yeung AR, Amdur RJ, Morris CG, et al. Long-term outcome after radiotherapy for FIGO stage IIIB and IVA carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2007;67:1445-1450.